Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine and cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
ChiCTR2200061816Phase 4Not yet recruiting
- Sponsor
- Army Medical Center
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in bladder cancer, sponsored by Army Medical Center. Primary endpoint: Pathological response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2200061816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061816.